Stephen Deutsch, M.D., Ph.D.
Dr. Deutsch received his
medical degree and Ph.D. in pharmacology at the New York University School of
Medicine. Dr. Deutsch completed his residency training in Psychiatry and a
research fellowship in Child Psychiatry at the Bellevue Psychiatric Hospital in
New York City where he worked with Samuel Gershon, Burt Angrist and Magda
Campbell. Dr. Deutsch was one of only 11 Pharmacology Research Associates
(PRAT fellows) in NIH's intramural research program. At the NIH, he worked in
Steven Paul's laboratory and developed an in vivo method for characterizing
benzodiazepines binding in brain. Using this method, Dr. Deutsch and his
colleagues showed that genetic factors, stress and hormonal manipulations
altered the binding characteristics of benzodiazepines in a regionally-selective
manner. In 1987, Dr. Deutsch was recruited jointly by the VA and Georgetown
University's Department of Psychiatry to become Chief of Psychiatry at the
Washington VA Medical Center. Dr. Deutsch's affiliation with the VA and
Georgetown has been uninterupted since 1987. Dr. Deutsch has published over 200
original articles and book chapters. He is the Associate Editor of Clinical
Neuropharmacology, reviews regularly for all of the major journals in his field,
and is a Fellow of the American College of Neuropsychopharmacology.
Ayman H. Fanous, M.D.
Dr. Ayman
Fanous serves as Staff Psychiatrist at the Mental Health Service Line at the
Washington VA Medical Center and Assistant Professor of Psychiatry at Georgetown
University Hospital. In addition, he serves as Assistant Clinical Professor of
Psychiatry at the Medical College of Virginia of Virginia Commonwealth
University. Dr. Fanous received his undergraduate degree in Philosophy from the
University of Virginia in 1990 and his medical degree from the Medical College
of Virginia in 1995. He completed his Residency in Psychiatry in 1999 at New
York University School of Medicine and received his post-doctoral training in
psychiatric genetics at the Virginia Institute for Psychiatric and Behavioral
Genetics. He is a member of the American Psychiatric Association and the
Bellevue Psychiatric Society.
Dr. Fanous' primary focus is the genetics of psychiatric illness, particularly
schizophrenia, suicidal behavior, and personality. He has been Principal
Investigator on a number of grants funding molecular genetic and twin studies
of these phenotypes. These have led to several first-author papers published
in journals such as Archives of General Psychiatry, American
Journal of Psychiatry, Molecular Psychiatry, American
Journal of Medical Genetics, and Psychological Medicine.
Richard B. Rosse M.D.
Richard B. Rosse, M.D. is a psychiatrist with over 150 publications in the peer- reviewed psychiatric literature, including the American Journal of Psychiatry, and book chapters in textbooks of psychiatry that include the Comprehensive Textbook of Psychiatry and is currently an Associate Professor of Psychiatry at Georgetown and also the Facility Service Line Manger for Mental Health at the Department of Veteran Affairs Medical Center in Washington, D.C. His current research interests include the role of neuropeptide Y in psychosis, the connection between appetitive gut and brain mechanisms and psychosis, augmentation of psychosocial rehabilitation strategies for patients with chronic mental illness, and detection of patients at risk of high risk events during hospitalization and after discharge.
Nina Schooler, Ph.D.
Nina R. Schooler, PhD, is currently Professor of Psychiatry at State
University of New York Downstate Medical Center; Adjunct Professor of Psychiatry
at the Georgetown University School of Medicine; Senior Research Psychologist
in the Veterans Affairs VISN 5 Mental Illness Research, Education, and Clinical
Center; and Senior Research Scientist at the Zucker Hillside Hospital. In these
capacities and settings, she conducts research on the treatment of schizophrenia
and its long-term course.
Prof. Schooler received her PhD in Social Psychology from Columbia University
and later served in leadership positions at the National Institute of Mental
Health (NIMH), where she led a series of significant multicenter clinical
trials of medication and psychosocial treatments for schizophrenia. She subsequently
joined the Department of Psychiatry at the University of Pittsburgh, where
she directed the Psychosis Research Program and was Professor of Psychiatry
and Psychology. She then served as Director of Psychiatry Research at the
Zucker Hillside Hospital , conducting research in treatment of first-episode
psychosis and negative symptoms in schizophrenia.
Prof. Schooler is a fellow of the American College of Neuropsychopharmacology,
the Collegium Internationale Neuropsychopharmacologicum, the American Psychological
Association, and the American Psychological Society. She has been President
of the American Psychopathological Association and the Association for Clinical
Psychosocial Research. She currently serves on the NIH Center for Scientific
Review Study Section for Behavioral Genetics and Epidemiology. She has published
widely in the peer-reviewed psychiatric literature and has served as an editor
for volumes relating to psychiatric clinical trials, clinical assessment,
and research methods.
Prof. Schooler's contributions to the field have been recognized by the Gralnick
Foundation-High Point Hospital Award from the Education and Research Foundation
of the National Association of Psychiatric Health Systems, the Alexander Gralnick
Research Investigator Award from the American Psychological Foundation, and
the Samuel Hamilton Award from the American Psychopathological Association.
Barbara L. Schwartz Ph.D.
Barbara L. Schwartz is an Associate Professor and psychologist in the Department of Psychiatry at the Washington Veteran's Affairs Medical Center, earning her Ph.D. in Experimental Psychology in 1988 at the University of Toronto. Her research examines memory and cognitive functions in individuals with neuropsychiatric disorders. The aim of the research is to understand how structural and functional disturbances in the brain disrupt the acquisition and retrieval of experienced events. A specific area of focus for the group has been to examine implicit (intuitive or “non-conscious”) memory and learning functions in persons with schizophrenia. Recent work examines implicit learning of facial expressions of emotion, and other aspects of social cognition, in schizophrenia. In addition, Dr. Schwartz has investigated the effects of N-methyl-D-aspartate (NMDA)-type glutamate agents on memory performance. The methodologies used to explore these research issues include behavioral and cognitive testing, psychiatric interviewing, brain imaging, and pharmacological interventions. Dr. Schwartz’s research is carried out in collaboration with her colleagues at the VA Medical Center and Department of Psychiatry at Georgetown University (Stephen I. Deutsch and Richard Rosse) and with colleagues in the Department of Psychology at Georgetown University (Darlene Howard and Chandan Vaidya) and Catholic University of America (James Howard, Jr.).
